KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Retained Earnings: 2010-2025

Historic Retained Earnings for TherapeuticsMD (TXMD) over the last 11 years, with Sep 2025 value amounting to -$951.8 million.

  • TherapeuticsMD's Retained Earnings rose 0.03% to -$951.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$951.8 million, marking a year-over-year increase of 0.03%. This contributed to the annual value of -$951.8 million for FY2024, which is 0.23% down from last year.
  • Per TherapeuticsMD's latest filing, its Retained Earnings stood at -$951.8 million for Q3 2025, which was up 0.02% from -$951.9 million recorded in Q2 2025.
  • TherapeuticsMD's Retained Earnings' 5-year high stood at -$918.3 million during Q1 2021, with a 5-year trough of -$1.1 billion in Q1 2022.
  • Moreover, its 3-year median value for Retained Earnings was -$951.5 million (2024), whereas its average is -$949.9 million.
  • As far as peak fluctuations go, TherapeuticsMD's Retained Earnings dropped by 22.07% in 2021, and later grew by 14.31% in 2023.
  • Over the past 5 years, TherapeuticsMD's Retained Earnings (Quarterly) stood at -$1.1 billion in 2021, then rose by 10.65% to -$939.4 million in 2022, then dropped by 1.09% to -$949.6 million in 2023, then decreased by 0.23% to -$951.8 million in 2024, then climbed by 0.03% to -$951.8 million in 2025.
  • Its Retained Earnings stands at -$951.8 million for Q3 2025, versus -$951.9 million for Q2 2025 and -$952.5 million for Q1 2025.